Anticoagulation with nadroparin in continuous venovenous hemofiltration (CVVH): extracorporeal clearance and systemic effects of nadroparin

Anticoagulation with nadroparin in continuous venovenous hemofiltration (CVVH): extracorporeal clearance and systemic effects of nadroparin - clearance and systemic effects of nadroparin in CVVH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29873

Enrollment

Registered

2006-12-04

Start date

2006-11-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(anti)stolling acute renal failure renal replacement therapy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: non-surgical patients in the ICU with indication of CVVH for acute renal failure

Exclusion criteria

Exclusion criteria: severe liver failure active bleeding and need for transfusion

Design outcomes

Primary

Measure	Time frame
· anti-Xa activity in plasma and ultrafiltrate · sieving coefficient of anti-Xa · clearance of anti-Xa in relation to CVVH dose	—

Secondary

Measure	Time frame
The course of anti-Xa and ETP in plasma Relation between anti-Xa and ETP in plasma	—

Countries

Netherlands

Outcome results